@article{d7064a1832064b578c3e35ad675add43,
title = "Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems",
keywords = "Alzheimer disease, Dementia, Health personnel, Magnetic resonance imaging, Medical colleges, Neurodegenerative disorders",
author = "Amy Brodtmann and David Darby and Carly Oboudiyat and Mahoney, {Colin J.} and {Le Heron}, Campbell and Panegyres, {Peter K.} and Bruce Brew",
note = "Funding Information: Amy Brodtmann has received fees for consultancy on the Biogen Australia, Roche Australia and Eisai Australia Scientific Advisory Boards. Bruce Brew reports speaker fees from AbbVie, Janssen and Viiv; consultancy fees for Eisai Australia Scientific Advisory Board; and speaker fees and grants from Biogen. Peter Panegyres has received consultancy fees from Biogen. David Darby has been on the Scientific Advisory Board for Biogen in the development of aducanumab, and has been an investigator for the Biogen ENGAGE and EMBARK trials. David Darby was an investigator for Roche trials of gantenerumab. ",
year = "2023",
month = apr,
doi = "10.5694/mja2.51880",
language = "English",
volume = "218",
pages = "247--249",
journal = "The Medical Journal of Australia",
issn = "0025-729X",
publisher = "Wiley-Blackwell",
number = "6",
}